Figure 2
Figure 2. A CCR4 antagonist combined with STxB-OVA breaks CD8+ T-cell tolerance against OVA in neuOT-I/OT-II TG mice. NeuOT-I/OT-II TG mice were immunized twice (day 0 and day 14) intraperitoneally with STxB-OVA (0.25 nmol) or OVA (0.25 nmol) mixed with αGalCer at day 0 and combined or not with a CCR4 antagonist (1.5 μg). One week later, splenocytes were harvested and semipurified with anti-CD8–coated magnetic beads. Detection of anti-OVA257-264 CD8+ T cells was performed either with Kb-OVA257-264 tetramer (as described in Figure 1A) or by IFNγ ELISPOT (B). These results are representative of 3 experiments with 4 mice per group. Values of P were calculated by the Mann-Whitney U test.

A CCR4 antagonist combined with STxB-OVA breaks CD8+ T-cell tolerance against OVA in neuOT-I/OT-II TG mice. NeuOT-I/OT-II TG mice were immunized twice (day 0 and day 14) intraperitoneally with STxB-OVA (0.25 nmol) or OVA (0.25 nmol) mixed with αGalCer at day 0 and combined or not with a CCR4 antagonist (1.5 μg). One week later, splenocytes were harvested and semipurified with anti-CD8–coated magnetic beads. Detection of anti-OVA257-264 CD8+ T cells was performed either with Kb-OVA257-264 tetramer (as described in Figure 1A) or by IFNγ ELISPOT (B). These results are representative of 3 experiments with 4 mice per group. Values of P were calculated by the Mann-Whitney U test.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal